Clinical trials: Obstructive Pulmonary Disease
Bronchial Asthma
Effect of High Dose Ciclesonide on Asthma Control
The aim of the trial is to investigate asthma control with 160 to 640 mcg ciclesonide/day. Asthma control will be assessed by the Asthma Control Questionnaire (ACQ).
- Trial name
- CONTRAST (NCT01455194)
- Testing
- Ciclesonide
- Where
- 30 sites in Argentina, Brazil and 3 more
- Volunteers
- 520 people
- Sponsor
- AstraZeneca
Asthma, Communication
Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults
Background: Asthma morbidity is high in inner-city minority adults, despite the existence of efficacious therapy. Tailored, patient-centered interventions are needed to improve access to care and patient-provider communication.
- Trial name
- NCT02086565
- Testing
- Portal training and home visits, Portal training
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- University of Pennsylvania
Asthma
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months with Asthma.
- Trial name
- NCT00809757
- Testing
- Levalbuterol, Levalbuterol UDV TID
- Where
- 46 sites in United States
- Volunteers
- 197 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function
This study will be a repeat-dose, double-blind, randomized, placebo controlled, three-way crossover study in patients with persistent bronchial asthma to compare the effect of morning (AM) and evening (PM) dosing with fluticasone…
- Trial name
- NCT01287065
- Testing
- FF(100mcg)/Vilanterol(25mcg) AM, FF(100mcg)/Vilanterol(25mcg) PM
- Where
- New Zealand
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Asthma
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00545272
- Testing
- indacaterol, formoterol, short acting β2-agonist
- Where
- 60 sites in Belgium, Czechia and 8 more
- Volunteers
- 392 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a…
- Trial name
- NCT01181895
- Testing
- Vilanterol, Salmeterol Inhalation Powder
- Where
- 34 sites in United States, Germany and 3 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted in the United States. The purpose of the study is to evaluate the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT01110200
- Testing
- ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
- Where
- 103 sites in United States, Argentina and 1 more
- Volunteers
- 639 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the…
- Trial name
- NCT03964207
- Testing
- Tiotropium Respimat® (T1), Tiotropium Handihaler® (T2)
- Where
- 8 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Asthma
Pharmacogenetics of b2-Agonists in Asthma.
This study will help to find out if having a certain genetic makeup influences how a person with asthma responds to salmeterol, one of the two drugs in Advair(R).
- Trial name
- NCT00708227
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Nemours Children's Clinic
Asthma
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on medium doses of ICS-LABA.
- Trial name
- NCT01947946
- Testing
- Benralizumab
- Where
- 47 sites in United States, Argentina and 5 more
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
- Trial name
- LABD (NCT00791518)
- Testing
- No intervention
- Where
- 57 sites in United States
- Volunteers
- 1,084 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/24 μg per day) over BDP HFA pMDI (800 μg per day) in terms of change from baseline to the entire treatment period in average pre-dose morning peak…
- Trial name
- FORCE (NCT01577082)
- Testing
- CHF1535 200/6 µg pMDI, BDP HFA 100 µg pMDI
- Where
- 66 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 542 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial
Asthma is an inflammatory disease that imposes a significant burden affecting an estimated 300 million persons and 20% of all children worldwide.
- Trial name
- MICT (NCT02061280)
- Testing
- fluticasone/salmeterol 250/50 Dry Powder Inhaler, fluticasone/salmeterol 100/50 Dry Powder Inhaler, fluticasone 100mcg Dry Powder Inhaler
- Where
- 5 sites in United States
- Volunteers
- 108 people
- Sponsor
- Nemours Children's Clinic
Asthma
Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler
This study aims to explore the potential impact of switching inhalers by assessing the handling error rate (critical and non-critical) in controlled asthmatics currently treated with, and using correctly, SERETIDE via the DISKUS…
- Trial name
- NCT02416180
- Testing
- SERETIDE MDI
- Where
- 7 sites in Germany
- Volunteers
- 111 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Veterans Integrated Service Network (VISN) 23 Lung Disease Self Management/Case Management Program
The purpose of this study is to determine if a program of self management and case management reduces hospitalizations and urgent care visits for patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00126776
- Testing
- case management, usual care
- Where
- 5 sites in United States
- Volunteers
- 743 people
- Sponsor
- US Department of Veterans Affairs
Asthma, Allergy
Dietary Interventions in Asthma Treatment: Sprouts Study
Sulforaphane (SFN) is a naturally occurring isothiocyanate that is a potent inducer of Phase II enzymes which play a critical role in preventing oxidative stress (via activation of Nrf2).
- Trial name
- NCT01183923
- Testing
- Broccoli Sprouts, Alfalfa Sprouts
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Asthma
Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)
Hypotheses: 1) Airway pH regulation is abnormal in severe asthma; 2) In severe asthma, there is formation of cytotoxic nitrogen oxides and loss of beneficial nitrogen oxides in the airways
- Trial name
- SARP (NCT00590005)
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Emory University
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with…
- Trial name
- NCT04795323
- Testing
- TARA v3.1, only non-pharmacological self-management support, TARA v3.2, both non-pharmacological and pharmacological self-management support
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs
For effective drug delivery using inhalation route, it is important to use the inhalers correctly. This open-label study will evaluate the error rates during the use of ELLIPTA DPI, alone or in combination, in comparison with…
- Trial name
- NCT03114969
- Testing
- Relvar ELLIPTA, Symbicort TURBUHALER, Seretide DISKUS
- Where
- 13 sites in Netherlands, United Kingdom
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.